Biohaven Pharmaceutical (NYSE:BHVN) PT Set at $55.00 by Morgan Stanley

Biohaven Pharmaceutical (NYSE:BHVN) received a $55.00 target price from Morgan Stanley in a research report issued on Monday, TipRanks reports. The firm presently has a “hold” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 23.60% from the stock’s previous close.

A number of other equities research analysts have also issued reports on BHVN. Goldman Sachs Group set a €75.30 ($87.56) price target on Stroeer SE & Co KGaA and gave the stock a “buy” rating in a research note on Monday, May 6th. Piper Jaffray Companies decreased their price target on Apyx Medical to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, May 8th. Barclays set a $145.00 price target on Sanderson Farms and gave the stock a “hold” rating in a research note on Friday, May 31st. Oppenheimer set a $68.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, June 19th. Finally, Needham & Company LLC decreased their price target on 2U to $75.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $70.00.

NYSE BHVN traded down $0.80 during trading on Monday, hitting $44.50. 479,953 shares of the stock traded hands, compared to its average volume of 750,697. The firm has a market capitalization of $1.98 billion, a P/E ratio of -7.24 and a beta of 0.25. The company has a 50-day moving average of $50.17. Biohaven Pharmaceutical has a 12-month low of $29.17 and a 12-month high of $67.86.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($1.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.09. During the same period in the prior year, the business earned ($2.32) earnings per share. On average, equities analysts anticipate that Biohaven Pharmaceutical will post -6.32 earnings per share for the current fiscal year.

In other news, CEO Vlad Coric acquired 5,000 shares of Biohaven Pharmaceutical stock in a transaction on Wednesday, June 26th. The shares were bought at an average cost of $40.22 per share, for a total transaction of $201,100.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John W. Childs acquired 10,000 shares of Biohaven Pharmaceutical stock in a transaction on Wednesday, June 26th. The shares were purchased at an average price of $40.37 per share, for a total transaction of $403,700.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 17,500 shares of company stock worth $712,425 over the last 90 days. 23.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BHVN. Neuburgh Advisers LLC purchased a new position in shares of Biohaven Pharmaceutical in the 4th quarter valued at $52,000. Manchester Capital Management LLC purchased a new position in shares of Biohaven Pharmaceutical in the 1st quarter valued at $52,000. NumerixS Investment Technologies Inc increased its holdings in shares of Biohaven Pharmaceutical by 333.3% in the 1st quarter. NumerixS Investment Technologies Inc now owns 2,600 shares of the company’s stock valued at $134,000 after acquiring an additional 2,000 shares during the period. Legal & General Group Plc increased its holdings in shares of Biohaven Pharmaceutical by 14.1% in the 4th quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock valued at $196,000 after acquiring an additional 652 shares during the period. Finally, Xact Kapitalforvaltning AB purchased a new position in shares of Biohaven Pharmaceutical in the 2nd quarter valued at $320,000. Institutional investors own 90.38% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Further Reading: Trading Stocks – What are percentage gainers?

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.